TY - JOUR
T1 - Paediatric non-infectious granulomatous uveitis
T2 - a retrospective cohort study
AU - Nguyen, Ai Tien
AU - Rousseau, Antoine
AU - Bodaghi, Bahram
AU - Rossi-Semerano, Linda
AU - Galeotti, Caroline
AU - Cunha, Elodie Da
AU - Eid, Laura
AU - Labetoulle, Marc
AU - Barreau, Emmanuel
AU - Titah, Cherif
AU - Toutée, Adélaïde
AU - Koné-Paut, Isabelle
AU - Dusser, Perrine
AU - Borocco, Charlotte
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
PY - 2025/3/1
Y1 - 2025/3/1
N2 - Introduction: Paediatric granulomatous uveitis (PGU) is rare. In addition, lack of awareness often leads to delayed diagnosis and poor visual outcome. Identifying the underlying cause and deciding how best to treat each patient is challenging. Objective: The objective of this study was to evaluate the demographics, aetiologies, complications, treatments, and visual prognosis of paediatric non-infectious granulomatous uveitis. Methods: A retrospective chart review of non-infectious PGU occurring in children before the age of 16 years (recruited from the Paediatric Rheumatology Unit, Bicêtre Hospital, France, from 2001 to 2023) was undertaken. Results: We included 50 patients with 90 affected eyes: 29 with idiopathic uveitis, 15 with sarcoidosis, 5 with JIA, and 1 with Vogt-Koyanagi-Harada disease. The median age at diagnosis was 9.8 years (range 7.2–12.5). The M:F sex ratio was 0.52. The most common types of PGU were: panuveitis (56%), bilateral (84%), and chronic (84%). Sarcoidosis was the most frequent diagnosis after idiopathic disease, particularly in the presence of lymphopenia and hypergammaglobulinemia. Uveomeningitis was present in 12% of cases. Upon diagnosis, ocular complications were present in 68 of 90 eyes (76%), particularly in cases of panuveitis. The most commonly used treatments were systemic CSs (72%) and MTX (80%). Twenty-three percent of eyes were in remission at last follow-up, 68% were inactive and 4% remained active. The median duration of follow-up was 5.8 years. Conclusion: We report the largest cohort of PGU. The cases of PGU were mostly idiopathic and had a high rate of complications. Sarcoid and idiopathic panuveitis are serious illnesses in which disease-modifying therapy should be initiated at diagnosis to improve management.
AB - Introduction: Paediatric granulomatous uveitis (PGU) is rare. In addition, lack of awareness often leads to delayed diagnosis and poor visual outcome. Identifying the underlying cause and deciding how best to treat each patient is challenging. Objective: The objective of this study was to evaluate the demographics, aetiologies, complications, treatments, and visual prognosis of paediatric non-infectious granulomatous uveitis. Methods: A retrospective chart review of non-infectious PGU occurring in children before the age of 16 years (recruited from the Paediatric Rheumatology Unit, Bicêtre Hospital, France, from 2001 to 2023) was undertaken. Results: We included 50 patients with 90 affected eyes: 29 with idiopathic uveitis, 15 with sarcoidosis, 5 with JIA, and 1 with Vogt-Koyanagi-Harada disease. The median age at diagnosis was 9.8 years (range 7.2–12.5). The M:F sex ratio was 0.52. The most common types of PGU were: panuveitis (56%), bilateral (84%), and chronic (84%). Sarcoidosis was the most frequent diagnosis after idiopathic disease, particularly in the presence of lymphopenia and hypergammaglobulinemia. Uveomeningitis was present in 12% of cases. Upon diagnosis, ocular complications were present in 68 of 90 eyes (76%), particularly in cases of panuveitis. The most commonly used treatments were systemic CSs (72%) and MTX (80%). Twenty-three percent of eyes were in remission at last follow-up, 68% were inactive and 4% remained active. The median duration of follow-up was 5.8 years. Conclusion: We report the largest cohort of PGU. The cases of PGU were mostly idiopathic and had a high rate of complications. Sarcoid and idiopathic panuveitis are serious illnesses in which disease-modifying therapy should be initiated at diagnosis to improve management.
KW - granulomatous
KW - idiopathic
KW - paediatric
KW - sarcoidosis
KW - uveitis
UR - https://www.scopus.com/pages/publications/86000145417
U2 - 10.1093/rheumatology/keae253
DO - 10.1093/rheumatology/keae253
M3 - Article
C2 - 38710493
AN - SCOPUS:86000145417
SN - 1462-0324
VL - 64
SP - 1333
EP - 1340
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 3
ER -